"Wegovy revenue climbed 79% to 17.3 billion Danish kroner ($2.5 billion), the Copenhagen-based drugmaker said on Wednesday, above analyst estimates. Sales rose by about 50% in the US, even as prices fell, after more insurers agreed to pay for the drug."
"This is good enough to provide some relief," Emily Field, a London-based analyst for Barclays, wrote in a note. The Wegovy beat came despite slightly worse pricing in the US than analysts had anticipated, Field said.
"Attention now will shift to Novo's next-generation obesity treatment, CagriSema, which is undergoing a large study that's due to deliver results by December."
Collection
[
|
...
]